Skip to content

Study · Animal study (in vivo) · mouse · 2025

3 results

Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.

Dong W, Bai J, Yuan Q, Zhang Y, Zhang Y, Zhang Z, Yang M, Li H, Zhao Z, Jiang H

EBioMedicine6 Jun 2025Cited by 11 (Europe PMC)

PMID40479843 (opens in a new tab)PMCIDPMC12205698 (opens in a new tab)DOI10.1016/j.ebiom.2025.105791 (opens in a new tab)PepBankPUB-40479843
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male db/db mice, mazdutide improved cognitive performance significantly more than dulaglutide in behavioural tests.

    In plain wordsIn diabetic mice, mazdutide improved thinking and memory test results more than dulaglutide.

    Peptide
    Mazdutide
    Outcome
    IncreaseCognitive performance in behavioural tests
    Study

    mousen: not reported in source

    Male db/db mouse (type 2 diabetes model)
    Comparator
    Dulaglutide
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to dulaglutide, mazdutide significantly improved cognitive performance in db/db mice, as evidenced by comprehensive behavioural tests.
    2 context sentences
    Summary · context
    This study aimed to investigate the effects of mazdutide on cognitive behaviour and cerebral pathology in male db/db mice, a model of T2DM, in comparison to dulaglutide, a GLP-1 receptor agonist.
    Summary · context
    All animal findings are applicable to male mice only.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male db/db mice, pathological assessment showed improvements in neuronal structure and brain tissue integrity in the mazdutide-treated group.

    In plain wordsIn diabetic mice, mazdutide-treated animals showed better brain cell structure and brain tissue.

    Peptide
    Mazdutide
    Outcome
    IncreaseNeuronal structure and brain tissue integrity
    Study

    mousen: not reported in source

    Male db/db mouse (type 2 diabetes model)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pathological assessments revealed improvements in neuronal structure and brain tissue integrity in the mazdutide-treated group.
    2 context sentences
    Summary · context
    This study aimed to investigate the effects of mazdutide on cognitive behaviour and cerebral pathology in male db/db mice, a model of T2DM, in comparison to dulaglutide, a GLP-1 receptor agonist.
    Summary · context
    All animal findings are applicable to male mice only.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In male db/db mice, multi-omics analyses identified distinct molecular pathways involved in neuroprotection, energy metabolism and synaptic plasticity with mazdutide.

    In plain wordsIn diabetic mice, gene, protein and metabolite analyses pointed to pathways linked to brain protection, energy use and nerve connections.

    Peptide
    Mazdutide
    Outcome
    Not applicableMolecular pathways in multi-omics analysis
    Study

    mousen: not reported in source

    Male db/db mouse (type 2 diabetes model)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Multi-omics analyses further identified distinct molecular pathways involved in neuroprotection, energy metabolism, and synaptic plasticity
    2 context sentences
    Summary · context
    This study aimed to investigate the effects of mazdutide on cognitive behaviour and cerebral pathology in male db/db mice, a model of T2DM, in comparison to dulaglutide, a GLP-1 receptor agonist.
    Summary · context
    All animal findings are applicable to male mice only.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.